Related Experiment Video
Updated: Dec 25, 2025
The Use of Reverse Phase Protein Arrays RPPA to Explore Protein Expression Variation within Individual Renal Cell Cancers
Published on: January 22, 2013
Atezolizumab for the treatment of renal cell carcinoma
Mathilde Lafon1, Charlotte Domblides1,2, Amaury Daste1
1Department of Medical Oncology, Bordeaux University Hospital , Bordeaux, France.
Introduction:
The therapeutic landscape of renal cell cancer has evolved rapidly over the past 2 years with nivolumab and ipilimumab for patients with metastatic disease and an intermediate or poor prognosis, in the first line setting. More recently, data from trials combining antiangiogenic agents and immune checkpoint inhibitors demonstrated a major benefit of this treatment approach for all patients.
Areas Covered:
One of three recent trials evaluated the combination of atezolizumab, an anti-programmed death ligand 1 antibody, with bevacizumab, an anti-vascular endothelial growth factor monoclonal antibody. In this manuscript, we summarize the preclinical, clinical, and safety data on atezolizumab for treatment of renal cell carcinoma and describe ongoing trials.
Expert Opinion:
Atezolizumab was evaluated in combination with an antiangiogenic agent. These trials were designed based on the hypothesis that selecting patients according to the expression of programmed death ligand 1 would increase the benefit of the treatment combination. Despite positive effects on the primary endpoints progression-free survival and response rate in this selected population, overall survival in the global population did not meet the criteria for significance at the time of the intermediate analysis. The major information was a proposed tumor gene expression signature. The signature was predictive of the sensitivity to anti-angiogenic and/or immune checkpoint inhibitor therapy.
Insights
The combination of atezolizumab and bevacizumab shows promise for renal cell carcinoma. A novel gene expression signature may predict patient response to this targeted therapy.
Area of Science:
- Oncology
- Immunotherapy
- Renal Cell Carcinoma Treatment
Background:
- The treatment for metastatic renal cell carcinoma (RCC) has advanced with immune checkpoint inhibitors and antiangiogenic agents.
- Recent trials explore combinations of antiangiogenic therapies and immune checkpoint inhibitors, showing significant benefits.
Purpose of the Study:
- To review preclinical, clinical, and safety data for atezolizumab in renal cell carcinoma.
- To discuss ongoing clinical trials involving atezolizumab for RCC treatment.
Main Methods:
- Evaluation of atezolizumab in combination with bevacizumab, an anti-vascular endothelial growth factor (VEGF) antibody.
- Hypothesis-driven trial design based on programmed death ligand 1 (PD-L1) expression for patient selection.
- Analysis of progression-free survival (PFS), response rate (RR), and overall survival (OS).
Main Results:
- The combination therapy demonstrated positive effects on PFS and RR in selected populations.
- Overall survival did not meet significance criteria in the global population at the interim analysis.
- A tumor gene expression signature was identified as predictive of treatment sensitivity.
Conclusions:
- Atezolizumab combined with antiangiogenic agents represents a developing treatment strategy for advanced RCC.
- The identified gene expression signature holds potential for personalizing treatment selection in RCC.
- Further research and ongoing trials are crucial to fully establish the role of atezolizumab in RCC therapy.
More Related Videos
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:27Tumor Immunotherapy
02:56Treatment Resistant Cancers
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...